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Abstract 
Hyperammonemia is a frequent complication of inherited deficiencies 
of^-ketothiolase, propionyl CoA carboxylase, and methylmalonvl CoA 
mutase. To probe the biochemical basis for such ammonia accumulation, 
I have determined whether a variety of organic acids (and their CoA 
esters) inhibit urea cycle enzyme activities in vitro in several orepara- 
tions of rat liver (crude homogenates, isolated mitochondria, and pure 
enzyme) and in crude homogenates of human liver. Neither tiglate, 
propionate, nor methylmalonate at concentrations as high as 10 mil 
inhibited c.arbamyl phosphate synthetase I (CPS I) or ornithine trans- 
carbamylase (OTC) activities in rat liver homogenates. Whereas the CoA 
esters of these organic acids also failed to impair OTC and arginase 
activities in this tissue preparation, they produced a significant, 
reproducible, concentration- and time-dependent inhibition of CPS I 
activity. This effect was not overcome by addition of the CPS I 
activator, N-acetvlglutamate (NAG), hence it was not secondary to the 
previously reported inhibition of NAG synthetase by several organic 
acids. Michaelis-Menten analysis showed that propionyl CoA, the most 
potent inhibitor, decreased tne V but did not alter the K 's for 
max m 
each of the CPS I substrates (ATP, ammonium, and bicarbonate). A 
concentration-dependent inhibition of CPS I by propionyl CoA was also 
demonstrated in isolated mitochondria and pure enzyme from rat liver 
as well as homogenates from human liver. The addition of dithiothreitol 
to the pure enzyme prior to assay resulted in a decrease in the degree 
of inhibition seen with propionyl CoA, implying that sulfhydryl groups 
are involved in the inhibitory effect. These data suggest that the 
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hyperammonemia seen in infants with these disorders may result, in part, 
from direct inhibition of CPS I by these acyl CoA esters. 

Part I; The Organic Acidemias and Hyperammonemia: A Review 
Inborn errors of amino acid metabolism include such diverse dis¬ 
orders as phenylketonuria and tyrosinemia, which result from defects 
of aromatic amino acid metabolism; cystathionemia and homocystinuria, 
which result from defects of sulfur-containing amino acid metabolism; 
and maple syrup urine disease and isovaleric acidemia, which result 
from defects of branched-chain amino acid metabolism. Most of these 
aminoacidopathies are associated with high morbidity and mortality 
which are related to the accumulation of substrates proximal to the 
defect: of the single enzymatic step which characterizes each disease (1). 
Early identification of these disorders may allow amelioration of the 
morbidity and mortality by decreasing the amount of the offending 
amino acids in the diet. 
Disorders of branched-chain amino acid oxidation in which amino 
acids do not accumulate have been called the "organic acidemias". 
Since the initial steps of this pathway are first a transamination 
to the corresponding keto acid and then an irreversible decarboxylation 
to the corresponding organic acid, any block distal to this decarboxyla¬ 
tion step will result in the accumulation of these organic acids, but 
not of the parent amino or keto acids (2). 
The discovery of the inherited "organic acidemias" was made possible 
by the development of new techniques for identification and characteri¬ 
zation of these organic acids, namely gas-liquid chromatography (GLC) 
and mass spectometry in conjunction with GLC (3). In 1966, Tanaka and 
colleagues (4) first used these techniques to identify isovaleric acid 
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in the blood and urine of a patient with the "distinct odor of sweaty 
feet" and a constellation of symptoms now considered to be characteris¬ 
tic for several of these organic acidemias. This clinical presenta¬ 
tion includes episodes of ketoacidosis with vomiting and lethargy, 
and coma or other neurological manifestations (3). The particular 
neurological abnormalities observed include: a Werdnig-Hoffman-like 
syndrome with infantile paralysis in a patient with ^-methylcrotonvl CoA 
carboxylase deficiency (5); ataxia and choreoathetosis in a patient 
with pyruvate carboxylase deficiency (6); and a familial dysautonomia- 
like picture with an abnormal histamine stimulation test in a patient 
with propionyl CoA carboxylase (PCC) deficiency (7). The cause of these 
neurological problems is unknown but they may reflect either a general 
neurological dysfunction secondary to severe metabolic acidosis or a 
specific dysfunction as in the case of PCC deficiency where increased 
amounts of propionyl CoA may substitute for acetyl CoA in fatty acid 
biosynthesis leading to the production of an abnormal myelin. 
Among the many recognized organic acidemias, three, -me thy 1- 
acetoacetic acidemia, propionic acidemia, and methylmalonic acidemia, 
share many clinical and biochemical features. First, each results 
from a deficiency of one of three mitochondrial enzymes^ B-ketothiolase, 
propionyl CoA carboxylase, and methylmalony1 CoA mutase, respectively, 
which catalyze successive steps in the major pathway of propionate 
metabolism. Second, each of these disorders may present with a similar 
clinical picture— severe acidosis with lethargy, vomiting and failure 
to thrive, mental and physical developmental retardation, hematologic 
abnormalities including neutropenia, anemia, and thrombocytopenia, 
and osteoporosis. Third, each has been associated with hyperglycinemia. 
' 
. 
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Prior to the elucidation of the precise biochemical defect in these 
disorders, children with deficiencies of each of these enzymes were said 
to have the "ketotic hyperglcinemia syndrome". In addition to hyper¬ 
glycinemia, these disorders are characterized by other biochemical 
abnormalities, including hypoglycemia, long-chain ketonemia and keto- 
nuria, and, as will be discussed further, hyperammonemia. The cause of 
these biochemical derangements is unknown, but they are almost certainly 
seondary to the primary deficiency in organic acid degradation (8). 
To understand the relationship between these primary defects and the 
secondary biochemical abnormalities, it is necessary to examine the 
major biochemical pathway of propionate metabolism. (See Figure 1) 
Isoleucine is transaminated and decarboxylated to the organic acid, 
<X-keto-/'-methylvaleric acid which undergoes further metabolism including 
addition to a Coenzyme A carrier and dehydrogenation to yield^K-methyl- 
acetoacetyl CoA. The latter intermediate is split by ^"-ketothiolase 
to yield propionyl and acetyl CoA’s. Other compounds including valine, 
threonine, methionine, odd chain fatty acids, and cholesterol side chains 
are also metabolized to propionyl CoA. Previously, it was thought 
that valine entered the Kreb’s Cycle through methylmalonyl CoA directly, 
but recent work has provided evidence that propionyl CoA is an obligate 
intermediate in this pathway (9). Propionyl CoA is carboxylated to 
D-methylmalonyl CoA by propionyl CoA carboxylase, a biotin requiring 
enzyme (10). Because only the L-isomer of methylmalonyl CoA is a 
substrate for methylmalonyl CoA mutase, D-methylmalonyl CoA undergoes 
racemization to the L-isomer in a reaction catalyzed by methylmalonyl CoA 
racemase. Finally, L-methylmalonyl CoA undergoes isomerization to 
succinyl CoA in a reaction catalyzed by methylmalonyl CoA mutase, a 
■ 
. 
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valine 
1 
©<-keto isovaleric acid 
I 
isobutyrl CoA 
I 
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D-methylmalonyl CoA 
methylmalony1 CoA racemase 
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methylmalonyl CoA mutase 
succinyl CoA 
Figure 1. Metabolism of the branched-chain amino acids valine and 
isoleucine 
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vitamin B^-requring enzyme (11). 
Vitamin B^> or more appropriately cobalamin (cbl) , metabolism 
has been extensively studied and this work is important in understanding 
the different abnormalities that can result in methylmalonic acidemia. 
Cbl is a cobalt containing vitamin with six cobalt-associated ligands; 
it occurs in a natural form, hydroxocobalamin (OH-Cbl), and a synthetic 
form, cyanocobalamin (CN-Cbl). These forms of cbl are not active as 
coenzymes but must be converted by the body to their active form by 
modification of the sixth ligand. Cbl absorption in the terminal ileum 
is dependent on the presence of a protein produced by the gastric 
parietal cells, intrinsic factor. The intrinsic factor- cbl complex 
binds to the mucosa of the terminal ileum, finally resulting in the 
release of free cbl into the blood. There, the cbl is bound to a serum 
protein carrier, transcobalamin II, which transports it to the cells of 
the body for metabolism and use. (See Figure 2) Once inside the cells, 
the cobalamin vitamin is transported into the mitochondria where it 
undergoes two enzyme-catalyzed reductions and, finally, adenosylation to 
yield 5'-deoxyadenosylcbl (Ado-Cbl), the active cofactor for methylmalonyl 
CoA mutase activity. OH-Cbl can also be converted, by a pithway which 
has not yet been elucidated, to methylcobalamin (Me-Cbl), the cofactor 
for N^-methyltetrahydrofdate : homocysteine methyltransferase , a key 
cytosolic enzyme in the pathway of sulfur-containing amino acid 
degradation and folate interconversion. 

Figure 2. Intracellular metabolism of OH-Cbl to active 
cofactors, (see following page) OH-Cbl is transported to 
the cell by transcobalamin II. Once inside the cell, 
OH-Cbl enters the mitochondrion where it is metabolized 
to Ado-Cbl, the active cofactor for methylmalonyl CoA 
mutase. Alternatively, OH-Cbl may remain in the cytosol 
where it is metabolized to Me-Cbl (by a pathway which has 
not yet been elucidated). 

/ 
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Figure 2. Intracellular metabolism of OH-Cbl to active cofactors, 
(see figure legend on proceeding page) 
. 
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Methylmalonic Acidemia 
As mentioned above, the organic acidemias are characterized by 
several secondary biochemical derangements, such as hyperammonemia, 
hypoglycemia, and hyperglycinemia. Proof that these derangements are 
indeed secondary to defects in organic metabolism first required the 
demonstration of the primary defects in the pathway of propionate 
metabolism. 
It has long been known that cbl is required for methylmalony1 CoA 
mutase activity (11); thus, the increased amounts of methylmalonic 
acid in the urine of patients with pernicious anemia (12), and with 
cbl deficiency for other reasons (13) were expected. In these reports, 
parenteral administration of physiologic amounts of cbl led to a dramatic 
fall in methylmalonate excretion. However, in 1967, two groups (14,15) 
described patients with increased methylmalonate excretion who had 
normal serum cbl concentrations. Stokke and colleagues (14) described 
a child who presented on the second day of life with irritability, 
a weak cry, decreased activity, hypotonia and irregular respirations 
who was found on laboratory examination to have severe metabolic acidosis 
with ketonuria, and transient thrombocytopenia. Methylmalonic acid 
was identified in this patient's urine by GLC and mass spectometry. 
The patient was given a trial of cbl without clinical response or decreased 
methylmalonate excretion. Further laboratory work in this child revealed 
14 14 
that C -valine loading resulted in excretion of C -methylmalonate 
and this led the investigators to postulate that the accumulation of 
methylmalonate was secondary to a defect in protein catabolism. The 
‘ 
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patient was started on a diet low in methylmaIonate precursors (isoleucine, 
valine, threonine, and methionine) and this resulted in improvement of 
the clinical condition and reduction in the tendency toward acidosis. 
With this diet, the excretion of methylmalonic acid fell from 800-1000 
mg/24 hours to 100-200 mg/24 hours (normal less than 5 mg/24 hours). 
Because the patient had two older sibs who had died in the neonatal 
period with similar clinical symptoms, these investigators thought that 
a "new" inborn error of metabolism was responsible for the increased 
excretion of methylmalonate. 
Oberholzer and colleagues (15) also described two children with 
persistent metabolic acidosis, vomiting, and physical and mental develop¬ 
mental retardation who had abnormally high methylmalonic acid excretion. 
They showed that valine, protein, or propionate administration led to a 
fall in plasma pH and bicarbonate level, an increase in plasma ketones, 
and hypoglycemia. In addition, all three of these substances augmented 
the much increased methylmalonate excretion. _In vitro tests with the 
two patients’ leukocytes revealed abnormal propionate metabolism. When 
white cells were incubated with propionyl CoA and NaHC^O^, C^-methyl- 
malonate was formed in normal amounts, but no conversion to succinic, 
fumaric, or malic acids was found. These findings were confirmed by 
Morrow and colleagues (16) in cultured fibroblasts. These groups con¬ 
cluded that these patients had a block in the conversion of methylmalonate 
to succinate but did not distinguish between a defect in the racemase 
or mutase. 
Rosenberg and colleagues (17) provided indirect evidence for a 
defect in the mutase enzyme in at least some of these patients by studies 
on a one year old boy with methylmalonic acidemia. They, too, found 
. 
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II 
that C^-propionate conversion to was negligible in leukocytes 
from this patient, but that succinate oxidation was intact. They 
concluded that the block was between propionate and succinate. Although 
this patient was not cbl-deficient, administration of large doses of 
parenteral CN-Cbl led to a fall in excretion of methylmalonate from 
800-1200 mg/24 hours to 220-280 mg/24 hours, and an increase in the 
amount of propionate oxidation to CO^ by intact leukocytes. In addition 
to providing indirect evidence for a mutase defect, this work established 
the concept of cbl-responsiveness in patientswith methylmalonic acidemia. 
The demonstration of "cbl-dependency" allowed patients with methyl¬ 
malonic acidemia to be divided into those that were cb1-responsive, i.e. 
showed decreased methylmalonate excretion with amelioration of symptoms 
after administration of pharmacologic doses of cbl despite the absence 
of cb1-deficiency (17-19), and those that were not (14,20,21). Other 
workers performed more detailed analyses on several of these patients 
with cbl-responsive methylmalonic acidemia in order to correlate clinical 
responsiveness (decreased methylmalonate excretion) with in vitro changes. 
Hsia and colleagues (22) obtained leukocytes from a cbl-responsive 
patient prior to cbl administration and showed that they failed to 
oxidize propionate or methylmalonate. However, oxidation was signifi¬ 
cantly increased in leukocytes after oral administration of cbl. Further, 
Morrow and colleagues (23) demonstrated that mutase activity in liver 
homogenates from a patient with cbl-responsive methylmalonic acidemia 
was increased to normal with the addition of saturating concentrations 
of Ado-Cbl to the incubation mixture. These groups concluded that methyl¬ 
malonic acidemia was genetically heterogeneous with cbl-unresponsive 
patients having a defect in the mutase apoenzyme and the cbl-responsive 
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patients having a defect either in Ado-Cbl synthesis or in the mutase 
apoenzyme such that it had a decreased affinity for Ado-Cbl. Either of 
the latter two defects could, theoretically, be overcome with pharma¬ 
cologic doses of cbl. 
Recently, much work has been done to characterize further the cbl- 
responsive forms of methylmalonic acidemia (24-29). To date, four 
classes of mutants with defective cbl metabolism have been discovered. 
Mahoney and colleagues (24) first distinguished two groups of cbl mutants, 
designated cbl A and B, which were distinguished by their ability to 
synthesize Ado-Cbl. Both cbl A and B mutants were unable to synthesize 
Ado-Cbl in intact cells, but in a broken cell system cbl A mutants had 
normal Ado-Cbl synthesis. These workers proposed that cbl A mutants 
represented either a defect in cbl transport across the mitochondrial 
membrane or an abnormality of the cbl reductase system, and that cbl B 
mutants probably had a defective adenosyltransferase (see Figure 2). 
Further work by Mahoney and Rosenberg (25) identified a third class of 
cbl mutants, cbl C, in which there was defective formation of both Ado- 
and Me-Cbl. Fibroblasts from cbl A and B mutants accumulated no Ado-Cbl, 
but Me-Cbl metabolism and intracellular concntrations were normal. On 
the other hand, cbl C mutants had undetectable levels of either Ado- 
or Me-Cbl. This class of mutants was thought to explain the previously 
reported association of methylmalonic acidemia with homocystinemia and 
cystathionemia (26). Gravel and colleagues (27) in work with inactivated 
Sendai virus-mediated heterokaryons showed complementation between cbl A, 
B, and C mutants demonstrating a genetic heterogeneity corresponding to 
the biochemical heterogeneity. 
' 
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Recently, evidence for a fourth class of cobalamin mutants, cbl D, 
has been described (28). Like cbl C mutants, the cbl D mutants lack 
mutase and methyltransferase activity, indicative of an absence of both 
Ado- and Me-Cbl; by complementation experiments, however, cbl C and D 
are genetically distinct. Neither class has been characterized biochemical¬ 
ly; cbl uptake is normal, however, suggesting abnormalities in one or 
more early cytosolic steps in the intracellular pathway of cbl coenzyme 
synthesis. 
A fifth class of in vitro cbl-responsive mutants has been found 
which does not complement with mutase apoenzyme mutants and has normal 
cbl metabolism. Willard and Rosenberg (29) have studied these two groups 
of apomutase mutants and have demonstrated that the cbl-responsive group, 
-A 
designated mut , have an altered K for Ado-Cbl (in the range of 10 M 
“8 
compared with 10 M for controls), reflecting decreased affinity of 
the enzyme for its cofactor. Mut mutants most likely represent base- 
pair substitutions which affect the Ado-Cbl binding site of methylmalonyl 
CoA mutase, but not the catalytic site. Mut^ mutations, on the other 
hand, have no residual mutase activity regardless of cofactor concentrations, 
and may represent a deletion or nonsense mutation which results in no 
apoenzyme production or production of a non-functional protein. 
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Propionic Acidemia 
In retrospect, the first patient with propionic acidemia was described 
by Childs and colleagues (30) in 1961. However, the increased excretion 
of propionic acid was not detected at that time and the disease was 
called "idiopathic hyperglycinemia" because of the increased glycine 
concentrations found in the patient's urine and blood. This patient 
presented at eighteen hours of life with vomiting, hyperpnea, acidosis, 
and ketonuria which persisted throughout the first week of life and 
resulted in a pyloromyotomy at age ten days. However, postoperatively 
the patient continued to vomit, failed to thrive, and had frequent 
infections; he was readmitted at eight weeks of age. At that time, 
he was found to have neutropenia, hypogammaglobulinemia, thrombocytopenia 
and purpura, and glycinuria. During the admission, it was demonstrated 
that the episodes of vomiting, lethargy, and ketosis could be terminated 
by withdrawal of oral feedings and intravenous administration of a 
glucose and electrolyte solution. Reintroduction of protein into the 
diet led to the symptoms of the acute illness with increased glycinuria 
and glycinemia. Challenge tests with the individual amino acids were 
well tolerated clinically except for leucine, methionine, isoleucine, 
threonine and valine, all of which resulted in vomiting and lethargy. 
The increased urinary glycine noted during these episodes led these 
workers to question whether the clinical and laboratory abnormalities 
were secondary to this increase. However, administration of sodium 
benzoate, which conjugates glycine to hippurate, did not prevent pro¬ 
duction of the typical metabolic acidosis, ketosis, vomiting, and 
lethargy in response to dietary protein loading despite a fall in 
. 
* 
glycinuria and glycinemia. Further, other workers (31) demonstrated that 
infusion of glycine into one of these patients resulted in neutropenia, 
but none of the other clinical or biochemical abnormalities. Both 
groups concluded that the increased glycine was not the cause of the 
periodic illness, but was secondary to some other abnormality related to 
protein degradation. 
Subsequent control of the illness in Childs' initial patient with 
a diet low in the offending amino acids, resulted also in a fall in 
glycine concentrations (32). Follow-up studies (33) in this patient 
two years after initiation of this special diet (age 4^) revealed that 
he had suffered a decreased frequency and severity of the periodic epi¬ 
sodes of ketosis, had no thrombocytopenia or neutropenia, and had de¬ 
creased infections. However, his growth was retarded with a height and 
weight well below the thirdpercentile, and his mental and physical 
development were delayed, including the inability to speak and the in¬ 
ability to walk without help. 
Although the primary defect remained obscure for many years, two 
"forms" of idiopathic ketotic hyperglycinemia were recognized. These 
two forms were called "acute" and "chronic" by Tanaka (3) and were 
differentiated by their age of onset and severity of symptoms. Hommes 
and colleagues (34) described a neonate who presented with hypotonia, 
areflexia, hyperventilation and grunting, and had a severe metabolic 
acidosis unresponsive to alkali therapy who died at five days of age. 
The early age of onset and the severity of the symptoms seen in this 
child are characteristic of Tanaka's "acute" group. At the other ex¬ 
treme, Brandc and colleagues (35) describe their experience with the 
sister of Childs' original patient. She had positive urinary ketones 
, 
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at 44 hours of life and was started on a special formula low in the 
offending amino acids. She was followed to age eight at which time she 
had evidence of only mild osteoporosis, but had normal height and weight, 
no thrombocytopenia, anemia, or neutropenia, and an IQ of 125. The 
mild nature of this child’s disease is characteristic of Tanaka’s "chronic" 
group. In between these two extremes were children like Childs' original 
patient who survived the neonatal period but suffered severe mental and 
physical retardation. This clinical heterogeneity was paralleled by 
a biochemical heterogeneity. For example, infants who were shown to 
have propionic acidemia were originally described without hypergly¬ 
cinemia (34) and without ketosis (36). This clinical and biochemical 
heterogeneity led workers to postulate that the spectrum of disease in 
patients with propionic acidemia was secondary to genetic heterogeneity 
at the locus which controlled the primary defect in protein metabolism. 
In 1968, Rosenberg and colleagues (17) noticed several similarities 
between patients with "idiopathic hyperglycinemia" and those with 
methylmalonic acidemia including protein induced ketosis and acidosis, 
long-chain ketonuria, and intermittent hyperglycinemia. These similari¬ 
ties led these workers to postulate that the defect in idiopathic 
hyperglycinemia was along the pathway of propionate metabolism, but 
since no methylmalonate was found in the urine, the block must be 
proximal to the production of methylmalonyl CoA. The finding by other 
groups (34,37) of increased propionic acid in the urine and blood of 
patients with idiopathic hyperglycinemia suggested that the primary defect 
in these children was a decrease in propionyl CoA carboxylase (PCC) 
activity. Other indirect evidnece for a defect in the PCC enzyme 
was found at autopsy of the patient described by Hommes at which a 
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fatty liver was found. Analysis of the stored triglycerides revealed 
unusual and straight chain fatty acids. These odd-numbered fatty 
acids were explained by a defect in the PCC enzyme resulting in a secon¬ 
dary increase in propionyl CoA which could serve as a substitute for 
acetyl CoA as a primer in fatty acid biosynthesis. In addition, products 
of alternate pathways of propionyl CoA metabolism, butanone (31) and 
propionylglycine (38), have been identified. 
More direct evidence for PCC deficiency in patients with ketotic 
hyperglycinemia came first from Hsia and colleagues (39) who demon¬ 
strated that peripheral leukocytes from a patient with propionic acidemia 
could not oxidize propionate to C09 as well as leukocytes from controls, 
although oxidation of methylmalonate was normal. Ando and colleagues (38) , 
in addition to confirming these _in vitro studies in fibroblasts from a 
patient with propionic acidemia, demonstrated that in_ vivo conversion of 
propionate to CC^ was defective. Synthesis of radiolabeled CoA derivatives 
of propionate and methylmalonate finally allowed direct measurement of 
PCC activity. Activity in leukocytes and cultured fibroblasts were 
reported by several groups (38,40,41) who found less than 2% of normal 
activity in each of three patients with propionic acidemia. 
Analagous to methylmalonyl CoA mutase, propionyl CoA carboxylase 
requires a coenzyme, biotin, for activity. Barnes and colleagues (42) 
described a patient with propionic acidemia who was not biotin deficient, 
but who responded clinically and biochemically to pharmacologic doses 
of biotin (10 mg/ 24 hours). This patient was maintained on a 0.1 gram 
protein/ kg diet and then given an isoleucine load, 0.1 g/ kg, which 
resulted in lethargy with metabolic acidosis, ketosis, hyperglycinemia 
and increased plasma propionate. This was repeated after giving 5 mg 
* 
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of biotin twice daily for five days. The fasting plasma propionate 
value, as well as the height and duration of the propionate response 
to isoleucine loading was significantly decreased as was the appearance 
of clinical symptoms. On the other hand, the patient described by Hsia 
and colleagues (40) did not respond to biotin supplements. Thus, as 
was described for methylmalonic acidemia, propionic acidemia has both 
vitamin-responsive and vitamin-unresponsive forms. The biotin is linked 
to the apoenzyme of PCC through an £-amino group of lysine by an apoenzyme- 
biotin ligase. An altered ligase or a PCC attachment site with decreased 
affinity for biotin which could be overcome with increased biotin are 
likely causes for the biotin-responsive variants of propionic acidemia. 
Biotin-unresponsive mutants most likely represent a mutation resulting 
in either a defective apoenzyme or absent enzyme production. 
The clinical heterogeneity, called "acute" and "chronic" by Tanaka, 
was not a function of this biotin-responsiveness, nor was it the result 
of the amount of residual PCC activity since some patients with the 
"chronic" form had less residual activity than those with the "acute" (43). 
Other work with Sendai virus-induced heterokaryons demonstrated two major 
complementation groups, designated pec A and pcc C (44). However, this 
genetic heterogeneity cannot explain the clinical differences since each 
complementation group is clinically heterogeneous. In fact, within the 
same family with two affected sibs, one child had severe coma leading to 
death, while the other was asymptomatic with normal intelligence (45). 
Tanaka concluded that the difference in clinical expression depends 
upon the balance between production and disposal of propionate, which 
depends, in turn, on the diet, and on the existence of alternate path¬ 
ways of removal, probably during a critical period of brain growth in 
. 
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the neonate (3). 
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<X -methylacetoacetic Acidemia 
In 1971, Daum and colleagues (46) described a child who presented 
at 22 months of age with symptoms compatible with the known disorders of 
propionate metabolism except that he ahd normal propionate and methyl- 
malonate concentrations in the body fluids. However, this child excreted 
abnormal amounts of two other organic acids, cX-methylacetoacetic and 
©<-methyl-^-hydroxybutyric acids. These workers suggested that this child 
had a new disorder of amino acid metabolism, which was later shown to be 
B-ketothiolase deficiency. This patient’s clinical course was mild with 
only five episodes of ketoacidosis before age five years, and normal 
physical and mental development. 
Other groups have subsequently described additional children with 
these clinical and biochemical characteristics who had more severe 
clinical findings. Keating and colleagues (47) described a child with 
projectile vomiting who underwent pyloromyotomy but continued to voinit and 
exhibit failure to thrive postoperatively. At age three months, he 
presented with lethargy, thrombocytopenia, hyperglycinemia and glycinuria, 
osteoporosis, hyperammonemia and long-chain ketonuria, all of which 
responded to a restricted protein diet. Isoleucine challenge after 
stabilization on this diet resulted in the recurrence of the above symptoms 
and findings. 
Daum and colleagues (48) reviewed the two pedigrees from their and 
Keating's patient and determined that, like propionic and methylmalonic 
acidemias, this new disorder could present anywhere in a spectrum of 
clinical and biochemical severity from mild intermittent episodes cf 
ketoacidosis with normal growth and development to severe recurrent 
' 
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episodes characterized by intermittent vomiting, metabolic acidosis, coma 
and the other biochemical features of the ketotic hyperglycinemia 
syndrome. These workers suspected that the abnormal clinical and biochemical 
findings were related to protein catabolism and demonstrated significant 
increases in the abnormal urinary metabolites in response to isoleucine 
loading. They proposed that the combination of normal propionate and 
methylmalonate concentrations with the buildup of the two substances 
proximal to the,/}-ketothiolase reaction, pointed to a defect in that enzyme 
as a cause of this new disorder. They proposed that the appearance of 
both of the abnormal metabolites was due to an equilibrium of the re¬ 
versible interconversion reaction between the two compounds, the balance 
of which, like the acetoacetate/V?-hydroxybutyrate ratio, depends on the 
NAD/NADH ratio in the cell. 
The localization of the defect was demonstrated more directly by 
Hillman and colleagues (49) who described a child who presented in the 
first week of life with symptoms of the ketotic hyperglycinemia syndrome. 
Metabolism of propionate and methylmalonate in leukocytes and cultured 
fibroblasts from this patient were normal. However, oxidation of isoleucine 
to C(>2 was less than 40% of controls. They concluded that this finding, 
along with the appearance of butanone in the urine (which was thought to 
be a metabolite of<X-methylacetoacetic acid), localized the defect to the 
/^-ketothiolase enzyme. 
Gompertz and colleagues (50) described a child who presented at 
seven years of age having survived childhood with only complaints of 
frequent episodes of abdominal pain, headaches and vomiting. They 
measured tiglyl CoA-dependent incorporation of tritiated water into 
. 
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propionate in leukocytes of this patient and found a significant decrease 
in activity compared to control cells. This localized the defect to one of 
two enzymes preceeding propionyl CoA in the pathway of isoleucine 
degradation. 
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Urea Cycle 
The primary defects in the pathways demonstrated above must, in some 
way, affect the turnover of ammonia in patients with these organic acidemias 
and lead to hyperammonemia. This effect may be an increase in ammonia 
production, i.e. negative nitrogen balance, decreased removal, i.e. im¬ 
pairment of the urea cycle, or both. In order to understand how a defect 
in organic acid metabolism may lead to hyperammonemia by this latter 
mechanism, it is first necessary to examine the urea cycle, its enzymes, 
and the control of its activity. 
Ammonia is formed primarily as the end product of amino and nucleic 
acid catabolism from the amide groups of glutamine and asparagine, the 
amine groups of glutamate and aspartate, and the amino groups of adenine, 
guanine and their derivatives. In addition, microbial deaminases and 
ureases found in the normal flora of the large intestine cleave amino acids 
and urea to ammonia which is absorbed by the gut and contributes to the 
blood ammonia pool. To prevent the buildup of ammonia and its consequent 
neurological toxicity, ammonia is removed via several pathways. First., 
ammonia is used in the synthesis of amino acids by reversal of several of 
the deamination reactions. In addition, ammonia can be used in purine, 
pyrimidine and porphyrin synthesis via incorporation into glutamine, 
carbamyl phosphate, and glycine. Lastly, and most important, ammonia is 
converted into nitrogen containing organic compounds, urea in mammals 
and uric acid in birds and reptiles, which are excreted from the body. 
Urea is formed in mammals via the urea cycle in which two moles of 
ammonia and one mole of carbon dioxide are consumed in the production 
. 
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of one mole of urea through a pathway of intermediates. That the liver 
is the major site of urea formation has been known since 1924 when 
Bollman and colleagues (51) demonstrated that removal of the liver in 
experimental dogs led to a decreased urea concentration in the blood. 
In 1932, Krebs and Henseleit (52) began the work in which the initial 
biochemical steps of the urea cycle were discovered. They demonstrated 
that urea could be synthesized in vitro in rat liver slices from ammonia 
and carbon dioxide (in the form of bicarbonate) and this began a search 
for other compounds that could act as a nitrogen donor to urea. One of 
the amino acids tested was ornithine. They found that one molecule of 
ornithine stimulated the formation of 20 molecules of urea when ammonia 
was present. However, the ornithine was not consumed in the process 
and the total urea nitrogen could be accounted for by the disappearing 
ammonia. These puzzling kinetics remained a mystery until the discovery 
of a pathway in which ornithine, carbon dioxide, and ammonia combine to 
form arginine. Along with the long known presence of an enzyme, arginase, 
which catalyzes the reaction in which arginine is split into ornithine 
and urea, the original ornithine cycle was proposed, (see Figure 3) 
ornithine 
NH, 
CO, 
arginine 
Figure 3. The original ornithine cycle as proposed by Krebs and Henseleit 
in 1932 
/ 
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Further work has elucidated the urea cycle as we now know it (see 
Figure 4), with five reactions catalyzed by the five major enzymes of the 
cycle. The initial step in the urea cycle is the fixation of one mole 
of ammonia and one. mole of carbon dioxide to form a high energy inter¬ 
mediate, carbamyl phosphate. This reaction requires ATP and is catalyzed 
by CPS I, an enzyme which uses ammonia as the nitrogen donor and which is 
found primarily in the mitochondrial matrix of liver cells. This enzyme 
is distinct from CPS II, an enzyme of pyrimidine biosynthesis found in 
the cytosol of most cells and which uses glutamine as a nitrogen donor (53). 
CPS I is a dimer of MW 250,000; each subunit is identical with MW of 
125,000 (54). This reaction requires, in addition to the substrates 
+2 . + 
mentioned above, Mg (needed for ATP binding) and K (increases the 
affinity of the enzyme for its substrates) (55). Two moles of ATP are 
consumed per mole of carbamyl phosphate formed: one mole is consumed in 
the dehydration of bicarbonate and yields a high energy intermediate 
which adds to ammonia to form another high energy intermediate thought to 
be carbanyl phosphate; and a second ATP that donates a phosphoryl group 
to carbamate to yield carbamyl phosphate (56). 
An important discovery about the CPS I reaction was made by Grisolia 
and Cohen (57,58) when they demonstrated that this reaction required a 
glutamate derivative as an activator. Their initial experiments used 
carbamyl glutamate, but six years later. Hall and colleagues (59) 
identified N-acetylglutamate (NAG) as the naturally occurring cofactor 
for carbamyl phosphate synthesis in mammalian liver. This was confirmed 
by work which demonstrated the presence of NAG synthetase, an enzyme 
found in the mitochondrial matrix which catalyzes the formation of NAG 
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Figure 4. The urea cycle. The mechanism of ammonia detoxification in 
mammals involves the condensation of nitrogens from ammonia and aspartate 
with CC^ to form urea tnrough the five enzyme cycle shown above. 
) 
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from L-glutamate and acetyl CoA and which is stimulated by L-arginine (60) . 
NAG causes a conformational change in CPS I which results in activation of 
the enzyme (54). 
Ornithine transcarbamylase (OTC) is an intramitochondrial enzyme 
which catalyzes the condensation reaction between carbamyl phosphate and 
ornithine to form citrulline (61). OTC from bovine liver is a trimer of 
MW 108,000; each subunit is identical and of MW 36,000 (62). Although 
trimers are unusual in mammalian systems, the demonstration of three 
binding sites for carbamyl phosphate (one per subunit) with three different 
dissociation constants, substantiates this earlier finding (63). Citrulline 
formed in this reaction is transported from the mitochondria to the 
cytosol on a specific carrier which is not energy dependent (64) . 
Cohen and Hayano first demonstrated that citrulline could be con¬ 
verted to arginine in rat liver slices (65). Ratner (66) demonstrated 
+2 
that Mg is required and that either aspartate or glutamate (in the 
presence of oxaloacetate) acted as the nitrogen donor. Much work was done 
in elucidating the enzyme system responsible for this ammonium transfer. 
Ratner and Pappas (67) demonstrated that two enzymes were required: the 
first catalyzed a condensation between citrulline and aspartate to yield 
an intermediate; the second cleaved this intermediate to arginine and 
malic acid. This intermediate was identified as argininosuccinate (68) 
and the reaction required one mole of ATP per mole of product formed (69). 
The enzyme that catalyzes this reaction is argininosuccinate synthetase. 
It is localized in the cytosol and has a MW of 180,000 with four identical 
subunits each of MW 45,000 (70). Associated with the synthetase enzyme 
is a pyrophosphatase which removes the inorganic phosphate formed and pulls 
efo 
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the condensation reaction in the direction of product formation (68). 
Argininosuccinase (argininosuccinic acid lyase) cleaves arginino- 
succinate to arginine and fumaric acid (71). (The finding of malic 
acid by earlier groups (67) was believed to be secondary to the fumarases 
present in the acetone-dried liver preparations used.) Argininosuccinase 
is a tetramer of MW 202,000. It contains four identical subunits 
weighing 50,000 daltons each (72), with one catalytic site per polypeptide 
chain (73). 
Finally, arginase splits arginine into urea and ornithine. Arginase 
+2 
is a Mn -requiring enzyme of MW 118,000 with four identical subunits 
weighing 30,500 daltons each (77). The ornithine formed enters the mito¬ 
chondria via an energy-dependent carrier which is specific for ornithine"1" 
but not arginine"*" or lysine"*", and is stereospecific for L-ornithine (67) . 
Regulation of the Urea Cycle 
The exact, mechanisms by which urea production is controlled are not 
known despite a considerable amount of work in this area. That a control 
mechanism does exist has been known since 1905 when Folin (75) demonstrated 
that urea production in normal adults was proportional to the intake of 
protein. Urea excretion fell within a day when a low protein diet in 
the form of a "starch and cream diet" (400 g pure starch and 300 ml of 
cream) was fed to his subjects; urea production increased within a day 
when a regular diet was reinstituted. 
The controversy over the control of urea production has been waged 
between those investigators who believe that control is mediated largely 
by changes in enzyme activities and those who believe that control is 
mediated by changes in substrate concentrations. Nuzum and Snodgrass (76) 
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demonstrated that an increase in the protein content of a monkey’s diet 
from 1.6 to 16 g protein/ kg resulted in a two to three fold increase in the 
activity of all urea cycle enzymes in liver homogenates _in_ vitro. Fur¬ 
ther, Schimke (77) showed that this increase in enzyme activity was linearly 
related to the increase in protein, and concluded that the increased urea 
production was due to increased enzyme activity.. Schimke isolated 
OTC and arginase from rats fed diets containing 15% and 60% protein and 
showed that both enzymes had the same pH optima, K^’s for substrates, 
MW, and turnover number regardless of the protein intake. He concluded 
that the increased activity of the urea cycle enzymes was due to an 
increased number of protein molecules and not to a change in the kinetic 
parameters of the molecules already present. The activities of the non¬ 
urea cycle enzymes measured such as glutamate dehydrogenase were not elevated 
at higher protein concentrations, so that the increase in urea cycle enzyme 
activities was not a non-specific increase due to more available amino 
acids for protein synthesis. Schimke followed the time course of the 
increase in activity and demonstrated that it was completed within four 
days for OTC, CPS I, and argininosuccinase and within eight days for 
arginase. 
Other workers argued that the augmentation of urea production must 
depend on the substrate load, not on the activity of the urea cycle enzymes, 
since the rate of urea excretion demonstrated by Folin changed more rapidly 
than the change in urea cycle enzyme activity described by Schimke. 
In support of this concept is the work by McGivan and colleagues (78) 
in which the rate of citrulline synthesis and the activities of the urea 
cycle enzymes were measured under different dietary conditions. In rats 
. 
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fed a high protein diet (egg whites), the rate of citrulline synthesis 
was increased 20 fold compared to rats fed 20% glucose. However, the 
maximal activities of the urea cycle enzymes did not differ greatly 
under these two dietary conditions. The disparity between these results 
and those of Nuzum and Snodgrass (76) and Schimke (77) remains unexplained. 
Tatibana and Shigsada (79) proposed that the regulation of urea 
production is accomplished via the acetylglutamate-arginine system, 
composed of two enzymes, CPS I and NAG synthetase, and their two acti¬ 
vators, NAG and arginine. They believe that glutamate and arginine are 
representative of the amino acid pool and that increases in these two 
amino acids reflect increased protein catabolism. Arginine stimulates the 
production of NAG (which is accomplished because of the increased amount of 
glutamate); NAG, in turn, stimulates the production of carbamyl phosphate. 
(In addition, arginine may supply ornithine, a critical rate-limiting 
substance.) In experiments with protein loaded mice, Shigesada and 
Tatibana (80) demonstrated that the NAG concnetration in mitochondria 
increased in parallel with the increased protein in the diet. When the 
percentage of the protein in the diet was increased from zero to 60%, the 
NAG concentration increased from 15 to AO nmoles/ g liver tissue. In 
1A 
addition, when C -glutamate was injected into three mice who were 
sacrificed 30 minutes, two hours, and nine hours later, NAG isolated from 
liver samples had 3900, 5900, and 260 cpm per g wet weight liver, respectively. 
This indicates that significant synthesis of NAG occurs within thirty 
minutes, a response quick enough to explain the increased urea production 
described by Folin. In further support of this hypothesis, these workers 
demonstrated that the increase in NAG paralleled the increase excretion 
, 
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of urea after protein loading (79). 
Further elaboration of this mechanism was reported in recent work 
by Stewart and Walser (81). Rats were sacrificed at certain time intervals 
after an intraperitoneal injection of a 1.5 g/ kg mixture of amino acids. 
Glutamate and NAG concentrations, as well as CPS I activity peaked five 
to fifteen minutes after injection. Surprisingly, this effect was 
reproducible and equal with or without arginine in the mixture, indicating 
that the increase in NAG was not secondary to an activation of NAG 
synthetase by arginine. These authors concluded that control of urea- 
genesis was, at least in part, via control of glutamate concentrations. 
According to this notion, protein loading results in increased concen¬ 
trations of glutamate which forms NAG and activates CPS I. At doses of 
amino acids of 3 g/ kg, CPS I activity was maximally activated and reached 
the same value seen in disrupted mitochondria with saturating concen¬ 
trations of NAG. Moreover, at doses of amino acids from 3-5 g/ kg, the 
autoregulatory mechanism became saturated and hyperammonemia supervened. 
Other authors have examined other steps in the urea cycle as possible 
control sites. Krebs and colleagues (82) suggest that since the of 
ornithine for OTC is 1.4 mM, the normal extracellular concentration of 
ornithine '.(0.3 mM) makes it likely that ornithine is rate-limiting 
in vivo. This may explain the reported stimulatory effect of ornithine 
on the urea cycle (52) , as well as recent work reported by Batshaw and 
colleagues (83) in which arginine infusions (as a source of ornithine) 
resulted in a fall in blood ammonia in infants with argininosuccinic 
aciduria. 
Finally, it has been suggested that ATP may be the rate-limiting 
reagent (84). In work in which animals were exposed to an anoxic 
. 
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challenge, the concentration, of ATP was lowered to less than 10% of nor¬ 
mal; this was accompanied by a significant rise in blood ammonia. 
Thus, the controversy continues between the "enzyme hypothesis" and 
the "substrate hypothesis". Changes in maximal enzyme activity as 
measured in vitro do not occur fast enough to account for the increased 
urea production, but this in_ vitro work may not accurately reflect the 
in vivo situation. Increased substrate concentrations may lead to 
increased urea production if enzymes are not fully saturated, but the 
in vivo effect of changes in substrate concentration awaits the accurate 
determination of intramitochondrial concentrations and comparison to 
values. It is likely that a system as complex as the urea cycle is 
regulated by changes in both substrate concentrations and enzyme activities. 
* 
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The Organic Acidemias and Hyperammonemia 
Several biochemical abnormalities including acidosis, hypergly¬ 
cinemia, hypoglycemia and hyperammonemia are common to each of the 
inherited organic acidemias and are thought to occur secondary to the 
primary defect in organic acid metabolism. Although hyperammonemia has 
not been considered a constant finding in all of these disorders, it is 
commonly found in infants with propionic acidemia (85,86), methylmalonic 
acidemia (20,87,88), and iX.-methylacetoacetic acidemia (47), and may 
contribute to the metabolic encephalopathy which so often occurs in 
affected newborns and young children. The precise mechanism of this 
hyperammonemia has not yet been identified, but much work has been done in 
an attempt to link the primary enzymatic defect with this secondary 
metabolic derangement. 
Rosenberg and colleagues demonstrated that isoleucine loading in 
two patients with propionic acidemia resulted in a significant increase 
in blood ammonia values which were correlated with rises in serum propionate 
(89). This work suggested that the buildup of a metabolite or precursor 
of propionate in the pathway of isoleucine degradation interferes with 
ammonia detoxification and leads to hyperammonemia. These workers pro¬ 
posed that this metabolite could directly inhibit one of the urea cycle 
enzymes or damage the mitochondria and interfere with the delivery of 
one of the substrates of these enzymes, e.g. decrease ornithine or 
citrulline transport across the mitochondrial membrane. 
Since the major pathway of propionate metabolism is located within 
the mitochondrion, the most likely site of action for any inhibitor 
would be on that portion of the urea cycle which occurs intramitochon- 
drially. This hypothesis was confirmed in work by Glasgow and Chase (90) 
. 
who demonstrated that 5 mM concentrations of propionate inhibited urea- 
genesis in vitro by 40 % in rat liver slices when ammonia, but not 
citrulline or aspartate, was the substrate. Propionate, however, had 
no effect on either CPS I or OTC activities when measured in rat liver 
homogenates. They concluded that this inhibition of ureagenesis (as well 
as the hyperammonemia seen in patients with the organic acidemias) was 
due either to a direct inhibition of CPS I or OTC by a metabolite of 
propionate, or to inhibition of citrulline or ornithine transport across 
the mitochondrial membrane, or to depletion of one of the substrates 
for the CPS I reaction. 
Several intramitochondrial sites for action of such a metabolite 
have been proposed. Some workers have presented evidence from in vitro 
experiments which favors the third possibility, namely that a decreased 
availability of one of the substrates of the CPS I reaction leads to the 
hyperammonemia. Cathelineau and colleagues (91) demonstrated that 
propionate decreased carbamyl phosphate concentration, citrullinogenesis, 
and ATP content. They proposed that this decreased ATP concentration 
and its consequent interference with CPS I activity could lead to hyper¬ 
ammonemia. However, Stewart and Walser (92) failed to find a decrease in 
ATP levels in mitochondria isolated from rats injected with 20 mmoles/ kg 
propionate or methylmalonate, doses which caused significant increases in 
blood ammonia. 
Other workers have focused on the role of N-acetylglutamate (NAG), 
the required allosteric activator of CPS I. Shigesada and Tatibana (60) 
initially described inhibtion of NAG synthetase by propionyl CoA, and 
Bachman (93) first proposed that such inhibition may account for the hyper 
ammonemia seen in infants with propionic and methylmalonic acidemias. 
If significant amounts of propionyl CoA build up behind the enzymatic 
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blocks in these disorders, NAG availability and, hence, CPS I activity 
could decrease, leading to hyperammonemia. 
Coude and colleagues (94) working iri vitro with rat liver mitochondria 
confirmed this inhibition and analyzed its kinetics extensively. They 
demonstrated that propionyl CoA was a competitive inhibitor of NAG 
synthetase and that the K is 0.71 mM, well within the range of propionate 
concnetrations observed in patients with these disorders. 
Recently, Stewart and Walser (92), working with an animal model for 
these disorders, have demonstrated that rats injected with 10-20 mmoles/ kg 
propionate or 20 mmoles/ kg methylmalonate and 1.5 g/ kg of an amino acid 
mixture developed hyperammonemia. Furthermore, although ATP levels were 
unchanged in mitochondria isolated from these rats, NAG content and CPS I 
activity were significantly decreased. Moreover, they demonstrated that 
acetyl CoA concentrations were significantly decreased while acyl CoA's 
(presumably propionyl and methylmalonyl CoA's) were increased. They 
suggested that NAG availability was decreased either because of competitive 
inhibition of NAG synthetase by propionyl CoA or from depletion of acetyl 
CoA. Thus, NAG depletion was highlighted as the putative mechanism 
for the hyperammonemia seen in patients with the inherited organic 
acidemias. However, these workers failed to show any decrease in NAG 
concentrations with injections of 10 mmoles/ kg methylmalonate, a dose 
v?hich led to significant decreases in acetyl CoA and an increase in 
blood ammonia. In addition, methylmalonyl CoA has been shown not to 
significantly inhibit NAG synthetase (60). 
Alternatively, propionyl CoA may act as a substrate for NAG synthetase 
leading to the production of N-propionylglutamate (NPG), a compound less 
effective as an activator for CPS I, which could compete with NAG for its 
* 
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CPS I binding site. That NPG is a weak activator of CPS I was confirmed 
by Coude and colleagues who demonstrated a for NPG of 1.1 mM, ten 
times the value obtained for NAG. A buildup of propionyl CoA, therefore, 
could result in the production of NPG instead of NAG, and consequently 
CPS I activation would be decreased and hyperammonemia would occur. 
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Part II: The Organic Acidemias and Hyperammonemia: Experimental 
Introduction 
All of the work summarized in the Review section suggests that 
organic acid accumulation impairs the intramitochondrial synthesis of 
carbamyl phosphate by decreasing the concentrations of CPS I substrates 
(ATP) or activators (NAG), or by favoring the synthesis of a much poorer 
activator (NPG). The present studies were undertaken to examine another 
hypothesis, namely that a metabolite in the pathway of branched-chain 
amino acid degradation directly inhibits one of the urea cycle enzymes. 
I have demonstrated that several acyl CoA's significantly inhibit CPS I 
activity in rat liver homogenates, disrupted mitochondria, and purified 
enzyme, as well as in human liver homogenates. 
* 
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Materials and Methods 
125 g female rats were purchased from Camm Laboratories in Wayne, N.J. 
and were fed a standard commercial diet- Rats were sacrificed by decapi¬ 
tation and livers were quickly excised. Liver for homogenates was quick 
frozen in dry ice and stored at -90&C until needed. Human liver was 
obtained from autopsy specimens within one hour of death, quick frozen 
and stored. 5% (w/v) homogenates for CPS I and arginase assays and 0.5% 
homogenates for OTC assays were prepared daily from frozen liver which 
was weighed wet and homogenized in distilled water. 
Preparation of Mitochondria 
Mitochondria were prepared from fresh rat liver using the method of 
differential centrifugation of Loewenstein (95) as modified by Fenton and 
colleagues (96). Liver from decapitated rats was excised, weighed wet, 
and suspended in a solution (SET solution) containing 0.25 M sucrose, 
17 mM Tris-HCl and 1 mM Na-EGTA pH 7.4 to make it 15% weight/ volume. 
The liver was minced with scissors and then homogenized with six to nine 
passes at 2100 rpm. The homogenate was centrifuged at 5000 rpm for one 
minute to remove the nuclear pellet and whole cells. The supernatant was 
recentrifuged for two minutes at 12,000 rpm. The pellet containing 
mitochondria and lysosomes was suspended in SET solution, 1 ml per gram 
starting liver. An equal volume of digitonin solution (1.75 mg/ml in SET 
solution), was added and the mixture gently agitated at 4°C for two 
minutes. This was then diluted to 5 ml/ gram starting liver and spun 
at 12,500 rpm for 4.5 minutes. The supernatant was removed and the 
, 
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pellet was washed twice in SET solution, 2 ml/ gram starting liver and 
centrifuged for 5.5 minutes. The yield from this procedure was generally 
about 1 g mitochondria per 100 g liver. 
Purified Enzyme 
Purified CPS I was obtained as a gift from Dr. Carol Lusty (97). The 
enzyme was stored frozen at -90°C in a buffer containing 50 mM Tris- acetate 
(pH 8.0), 2 M ammonium sulfate, 0.1 M sodium acetate, 0.01 M magnesium 
acetate, and 2 mM dithioerythritol. The frozen sample was thawed just 
prior to use and the cations were removed by the technique of Sephadex 
centrifugation as described by Lusty (98). G-50 (fine) Sephadex was 
equilibrated with 0.05 M Tris-acetate buffer, pH 8.0 (4°C) and a column 
was poured into a one ml tuberculin-type syringe. The column was washed 
with two volumes of this buffer and then packed by centrifugation for 
three minutes at 100 X g. A sample of enzyme preparation (10-100 micro¬ 
liters) was brought to a final volume of 100 microliters with buffer and 
placed on the top of the column. The enzyme was collected by centrifuga¬ 
tion for 3 minutes at 100 X g and then diluted in buffer containing 50% 
glycerol. No dithioerythritol or dithiothreitol was added to the enzyme 
at the end of the procedure unless noted below. 
Hepatic Enzyme Assays 
CPS I activity in liver homogenates was determined by the colorimetric 
measurement of citrulline synthesis using a modification of the method 
of Erown and Cohen (99). The final assay volume was 0.1 ml containing 
0.01 ml 5% homogenate, 10 mM NAG, 20 mM ATP, 20 mM MgCl^, and 50 mM 
NH^HCO^. The latter three reagents were added as part of a mix which was 
added to initiate the reaction and also contained 40 mM Tris-HCl buffer, 
- 
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(pH 7.5), 9 mM ornithine, and 0.5 units purified bovine OTC. The final 
reaction was ay pH 7.2. Reaction mixtures were incubated for ten minutes 
at 37°C; reactions were terminated by the addition of 0.1 ml 10% tri¬ 
chloroacetic acid. A boiled enzyme blank, zero-time blank, and blank 
without NAG gave similar results and hence a zero-time blank was used. 
Color development was carried out using a modification of the method of 
Archibald (100). Each tube contained 0.15 ml from the assay mixture, 
0.85 ml of water, and 3 ml of a solution which contained 1 volume diacetyl 
monoxime (200 mg in 50 ml 7.5% NaCl) and 2 volumes acid solution (1.85 g 
antipyrine and 1.25 g ferrous ammonium sulfate in 250 ml water added to 
125 ml concentrated phosphoric acid and 125 ml concentrated sulfuric acid) 
Citrulline standards of 2.5 to 10 micrograms were made from a solution 
which contained 15 mg% citrulline in 0.1 N HC1 diluted 1:2 with water. 
All tubes were put into a boiling water bath for 30 minutes and then 
cooled. A was read for the sample tubes and compared to standard 
values. Inhibitors were added just prior ro the initiation of the 
assay. All reactions were run in duplicate with control tubes in each 
study. Control activities in rat liver homogenates ranged from 2.0-2.8 
umoles/hr/mg protein and in human liver homogenates from 0.8-1.0 umoles/ 
hr/mg, both in agreement with data from other authors (101). 
Measurement of CPS I activity in isolated mitochondria was performed 
using the above assay conditions after gentle sonification (setting 1 on 
a Branson cell disrupter 185) of the mitochondria at 4°C for 30 seconds. 
Final pH was 7.2. A zero-time blank was used. Control activities for 
rat liver mitochondria assayed at 37°C were 9.6-12 umoles/hr/mg mito¬ 
chondrial protein, which is in agreement with other authors (101) . 
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Control activity at 30°C was 4.0 umoles/hr/mg. This temperature dependence 
is in agreement with other work (58). 
CPS I activity in purified enzyme preparations was determined using 
the above assay conditions. Protein content was determined from the 
A280' assum;*-n9 an 0D reading of 1.0 for a solution with a concnetration 
of 1 mg/ml. Control activity was 120 umoles/hr/mg, in agreement with 
other work (97). 
OTC activity in rat liver homogenates was measured by the colorimetric 
determination of citrulline synthesis as described by Nuzum and Snodgrass 
(101). The final assay volume was 0.1 ml containing 0.01 ml of 0.05% 
homogenate, 10 mM ornithine and 10 mM carbamyl phosphate. The mixture 
was incubated for 15 minutes at 37°C and the reaction was terminated by 
the addition of 0.1 ml 10% trichloroacetic acid. Color development was 
carried out as described above except that each tube contained 0.9 ml of 
water and 0.1 ml from the assay. Control activity was 67 umoles/hr/mg, 
in agreement with other authors (101). 
Arginase activity in rat liver homogenates was measured using the 
colorimetric determination of urea synthesis by a modification of the 
method of Nuzum and Snodgrass (101). 0.01 ml of a 5% liver homogenate 
was preincubated with 0.09 ml 1% bovine serum albumin, 0.5 ml 0.07 M gly¬ 
cine, 0.05 ml 0.3 M NaCl, and 0.1 ml 0.1 M MnC1^ for one hour at 37°C. 
The assay mixture contained 0.2 ml 375 mM arginine, pH 9.5, and 0.1 ml 
of the above incubation mix. This mix was assayed for 10 minutes at 
37°C and the reaction was terminated by the addition of 0.1 ml of 20% 
trichloroacetic acid. Color development was carried out by mixing 0.2 ml 
of the assay mixture, 2 ml of an acid reagent containing 18 ml of 
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concentrated sulfuric acid, 54 ml of concentrated phosphoric acid and 
0.2 ml 0.1 M FeCl^, and 0.1 ml 3% 1-phenyl-l,2-popane dione-2-oxime in 
95% ethanol. Urea standards were prepared from a stock solution con¬ 
taining 25 mg% urea in 0.1 N HC1. All tubes were placed in a boiling 
water bath for one hour in the dark and then cooled. Ar<„ was read for 
540 
each sample and compared to standards. Control activity v/as 500 umoles 
urea/hr/mg, in agreement with other authors (101). 
Protein was determined by the method of Lowry (102), unless as 
otherwise noted above. Diluted samples were added to 5 ml of a solution 
containing 0.5 ml 1% CuSO^, 0.5 ml 2% sodium tartate, and 50 ml 2% Na CO 
in 0.1 N NaOH. This mixture was incubated for 10 minutes at room tempera¬ 
ture and then 0.5 ml 2 N Phenol Reagent (Fisher), diluted 1:1 with water, 
was added and incubated for 30 minutes more at room temoerature. A^,. 
625 
was read for each sample and compared to known concentrations of bovine 
serum albumin. 
Inhibitors 
Potential inhibitors selected for study were organic acids in the 
pathway of isoleucine degradation, as well as their CoA esters. Inhibitors 
were added just prior to the initiation of the assay unless specified. The 
pH of the final assay mixture was measured with each inhibitor and there 
was no significant difference from control. The organic acids and iso¬ 
leucine were purchased from Sigma. Methylcitrate was a gift from Dr. Kay 
Tanaka. The CoA esters were purchased from PL Biochemicals with the 
exception of methylmalonyl CoA which was the gift of Dr. Wayne Fenton 
and propionyl CoA which was synthesized as described below. 
Propionyl CoA was synthesized from propionic anhydride (Eastman) 
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and Coenzyme A (PL Biochemicals) following a modification of the method 
of Flavin and Ochoa (103). 500 mg of coenzyme A was added to 30 ml of 
1 M ammonium bicarbonate (pH 9.0), 7 ml of propionic anhydride and 33 ml 
of ethanol. The propionyl CoA formed was extracted three times with ether, 
adding an equal volume of ether and water. The excess ether was removed 
by vacuum suction extractions. After the final extraction, the propionyl 
CoA was lyophilized and resuspended in 4 ml of water. The concentration 
of propionyl CoA in the final solution was calculated by measurement of 
the A232' us^n<? an extinction coefficient of 7.85. 
Calculation of Enzyme Inhibition 
Calculations of enzyme inhibition were complicated by the fact that 
the acyl CoA's inhibited the colorimetric reactions used to determine 
CPS I, OTC, and arginase activities. To correct for suppression of 
color development, propionyl or other CoA's were added to assay blanks 
(i.e. without homogenate), carried through the assay procedure, added to 
standard concentrations of citrulline and urea, and finally carried through 
the color development process. These were compared to similar standards 
containing no CoA esters to obtain an estimate of color suppression. 
Enzyme inhibition was calculated using the formula (Observed activity 
with inhibitor) = (Control activity) X (1 - fraction of enzyme inhibition) X 
(1 - fraction color suppression), solving for fraction of enzyme inhibi¬ 
tion. Figure 5 demonstrates the effect of propionyl CoA at concentra¬ 
tions of 0, 1, 3, and 8 mM in suppressing colorimetric determination of 
citrulline. At each concentration of propionyl CoA, the fractional 
residual color developed at (i.e. (1 - fraction color suppression)) 
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is equal for all concentrations of citrulline: for 1 mM propionyl CoA, 
0.95; 3 mM, 0.85; and 8 mM, 0.65. 
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CITRULLIME {/jlq) 
Figure 5. Suppression of the color development reaction used to 
determine the rate of citrulline synthesis by propionyl CoA. 
Calculations of CPS I inhibition by propionyl CoA were complicated 
by the fact that CoA esters inhibit the colorimetric reaction used 
to measure CPS I activity as well as the enzyme. To obtain an 
estimate of the amount of color suppression, various concentrations 
of propionyl CoA were added to known amounts of citrulline, run 
through the color development process, and then compared to 
citrulline standards. For each concentration of propionyl CoA, 
the fractional residual color (i.e. 1 - fractional color suppression) 
was equal for ail concentrations of citrulline: for 1 ml 1 propionyl 
CoA, 0.95; 3 mM, 0.85, and 8 mM, 0.65. 
. 
Results 
Selective Inhibition of CPS I Activity in Rat Liver by CoA Esters 
The effects of various metabolites on the iii vitro activities of 
three urea cycle enzymes were tested. The results shown in Table 1 
demonstrate that neither propionate, methylmalonate, tiglate, methylcitrate, 
nor isoleucine at concentrations of 10 mM inhibited CPS I or OTC activi¬ 
ties in rat liver homogenates. Further, neither CoA nor the CoA esters 
of several of these organic acids affected the activity of OTC or 
arginase. In sharp contrast to these latter results, however, CPS I 
activity was regularly and significantly impaired when 10 mM concentrations 
of CoA, tiglyl CoA, methylmalonyl CoA, or propionvl CoA were added at the 
point of initiation of the enzyme assay. Table 1 shows data from a 
single representative experiment in which free CoA reduced activity 
by 35%, the acyl CoA's by considerably more. Propionyl CoA was regularly 
the most potent inhibitor, reducing activity by 72% in this study and 
by an average of 71 + 5% in experiments with three different rat livers. 
Concentration-Dependent and Time-Dependent Inhibition of CPS I Activity 
Using propionyl CoA as the model inhibitor in further experiments, 
I demonstrated that the inhibition of CPS I activity in crude homogenates, 
in isolated mitochondria, and of purified enzyme .is a function of the 
propionyl CoA concentration. When varying concentrations of propionyl CoA 
(0-10 mM) were present only during the ten minutes of enzyme assay, 
inhibition of CPS I activity increased from 35% at 1 mM to 70% at 10 mM 
(Figure 6). At each concentration of propionyl CoA tested, inhibition 
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Table 1: Inhibition of urea cycle enzymes by • various metabolites in 
pathway of isoleucine degradation 
Inhibition of ; Enzyme Activity (%) 
Compound CPS I OTC Arginase 
propionyl CoA 72 (4) 0 (2) 0 (2) 
methylmalonyl CoA 66 (2) 0 (2) * 
tiglyl CoA 49 (2) 0 (2) * 
CoA 35 (2) 0 (2) 0 (1) 
methylcitrate 4 (2) 0 (2) * 
isoleucine 2 (2) 0 (2) * 
tiglic acid 0 (2) 0 (2) * 
methylmalonic acid 0 (2) 0 (2) * 
propionic acid 0 (2) 0 (2) 0 (1) 
Urea cycle enzyme activities in rat liver homogenates were assayed in the 
presence of 10 mM inhibitor added just prior to the initiation of the assay. 
The data presented are the averages of duplicate tubes run in a single 
representative experiment. Control activities were: CPS I 2.6 umoles/hr/mg? 
OTC 67 umoles/hr/mg; and arginase 500 umoles/hr/mg. The numbers in the 
parentheses refer to the number of experiments done with each inhibitor at 
this concentration. * = not tested. 
was slightly greater with the crude homogenates and isolated mitochondria 
than with purified CPS I, but the difference among the various tissue 
preparations was small compared to the overall magnitude of the inhibitory 
effect. 
When homogenates were incubated with propionyl CoA prior to initiating 
the CPS I assay, the inhibitory effect was noted to be time-dependent. 
' 
- 
4 
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o 
[PROPIONYL CoA ] mM 
Figure 6. Concentration-dependent inhibition of CPS I by propionyl 
CoA. CPS I activity in crude homogenates, in disrupted mitochondria, 
and of pure enzyme from rat liver was measured in the presence 
of varying concentrations of propionyl CoA (0-10 mM), added at the 
point of initiation of the enzyme assay. Control activities were: 
homogenate, 2.4 umoles/hr/mg; mitochondria, 11 umoles/hr/mg; and 
pure enzyme, 120 umoles/hr/mg. 
- 
■ 
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In the experiment shown in Figure 7, homogenates were incubated with 2.5 mli 
propionyl CoA and 25 mM NAG for 0-30 minutes and then were assayed for 
CPS I activity in the presence of 1 mM propionyl CoA. The data demonstrate 
that the inhibitory effect increased linearly from 45% with no prior 
incubation (i.e. 10 minutes of total exposure) to 66% when the enzyme 
was incubated with the inhibitor for 30 minutes prior to assay (i.e. 
40 minutes of total exposure. The linearity of the curve suggests that 
with total exposure times greater than 40 minutes, CPS I activity would 
likely have been inhibited even more. 
A recent paper (94) reported that the inhibition of CPS I activity 
in isolated rat liver mitochondria by 10 mM propionyl CoA was only about 
c 15% at 30 C, significantly less than the 70% inhibition seen in the present 
experiments conducted at 37°C. To determine if these disparate results 
reflected the different temperatures used, I carried out experiments at 
both 30°C and 37 °C. Table 2 shows that CPS I activity in isolated 
mitochondria was inhibited comparably by 3 mM concentrations of 
propionyl CoA at both temperatures (43% at 30cC; 40% at 37cC). 
Table 2: Effect of incubation temperature on inhibition of CPS I activity 
in disrupted mitochondria by propionyl CoA 
CPS I Activity (umoles/hr/mg) 
Temperature (UC) control + 3 mM propionyl CoA 
30 7.2 4.1 
37 4.0 2.4 
CPS I activity was assayed in disrupted mitochondria at 30° C and 37'" C 
in the presence and absence of 3 mM propionyl CoA. Data shown are averages 
of duplicate tubes from one of two identical experiments. 
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MINUTES OF TOTAL CPS I EXPOSURE 
TO PROPIONYL CoA 
Figure 7. Time-dependent inhibition of CPS I by propionyl CoA. CPS I 
activity in crude rat liver homogenates was assayed in the presence 
of 1 mM propionyl CoA after incubation of the enzyme with 2.5 mM 
propionyl CoA. Control activity was 205 umoles/hr/mg and did not 
vary in control incubations from 0-30 minutes without propionyl CoA. 
■ 
* 
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Mechanism of Propionyl CoA Inhibition 
To characterize further the mechanism by which propionyl CoA impairs 
CPS I activity, Michaelis-Menten kinetic analyses were carried out in 
rat liver homogenates with each of the enzyme's substrates (ATP, ammonium, 
and bicarbonate). Double reciprocal transformation of substrate vs. 
velocity curves yielded linear plots from which the apparent K 's and 
m 
V 's could be calculated. As shown in Table 3, 3 mM propionyl CoA 
max J 
reduced the maximal velocity of CPS I activity by about 50% regardless 
of which of the enzyme's substrates was varied. Significnatly the apparent 
K 's for each substrate were not affected by the propionyl CoA. 
m 
Table 3: Kinetic parameters of rat liver CPS I in the presence and absence 
of 3 mM propionyl CoA 
Substrate 
V (umoles/hr/mg)* 
—max--— 
control + 3mM propionyl CoA 
K (mM) * 
—m- 
control + 3mM propionyl CoA 
ATP 
+ 
NH 
4 
HCO~ 
2.09 
1.95 
2.53 
1.04 
1.02 
1.38 
3.2 
0.53 
3.2 
3.3 
0.45 
2.7 
*Kinetic parameters were determined in rat liver homogenates by varying the 
concentration of one substrate while keeping the other two substrate con¬ 
centrations constant. K 's and V 's were derived from plots of 
1/velocity vs. l/substra5!e concentration. Substrate concentrations were 
varied as follows: for ATP 1, 2, 4, and 20 mM; for NH^ 0.25, 1, 2, 5, and 
50 mM; and for HCO~ 1, 2, 10, and 50 mM. 
' 
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To insure that the effect of propionyl CoA on CPS I was not secondary 
to the described inhibition of NAG synthetase, the NAG concentration in 
all of our assays was 10 mM, 100 times its reported K (98). Furthermore, 
3 
increasing the concentration of NAG to 100 mM did not decrease the 
magnitude of the inhibitory effect of propionyl CoA seen in homogenates, 
isolated mitochondria, or purified enzyme. 
In experiments with purified enzyme from rat liver, the addition 
of dithiothreitol (DTT) to the enzyme after passage through the Sephadex 
column reduced the degree of inhibition produced by propionyl CoA. 
Table 4 demonstrates that addition of 2 mM DTT reduced inhibition of 
CPS I by 3 mM propionyl CoA from 57% to 24%. Increasing the concentration 
of DTT to 4 mM had no further effect. 
To determine the reversibility of propionyl CoA inhibition of CPS I, 
purified enzyme was incubated with 3 mM propionyl CoA for 15 and 30 
minutes, passed through a Sephadex column to remove the propionyl CoA 
and then assayed. The data shown in Table 5 demonstrate that removal 
of the propionyl CoA from the assay mixture led to complete loss of 
its inhibitory effect. 
Table 4: Inhibitory effect of 3 mM propionyl CoA ■ with varying concentrations 
of dithiothreitol (DTT) . . 
CPS I activity (umo1e s/hr/mg) 
DTT (mM) control + 3 mM propionyl CoA 
0 72 31 
2 83 63 
4 76 59 
CPS I activity was assayed in pure enzyme preparations to which varying 
concentrations of DTT were added after passage of the enzyme through the 
Sephadex column used to desalt the enzyme from the storage buffer. Activity 
with each preparation was measured in the presence and absence of 3 mM 
propionyl CoA. Data are from one of two identical experiments with 
similar results. 
* 
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Table 5: Reversibility of propionyl CoA inhibition of CPS I 
CPS I activity (umoles/hr/mg) 
Incubation time (mins) control + 3 mM propionyl CoA 
0 74 
15 66 70 
30 80 76 
CPS I activity was measured using pure enzyme preparations incubated for 
varying times with 3 mM propionyl CoA, passed through a Sephadex column to 
remove the propionyl CoA and then assayed. Control preparations incubated 
without propionyl CoA were also assayed. 
Results with Human Liver 
Finally, very similar results were obtained when CPS I activity was 
assayed in homogenates of post mortem human liver. Thus, 10 mM propionate 
had no effect on human hepatic CPS I activity, whereas propionyl CoA, 
at concentrations of 1 mM or greater, impaired CPS I activity in human 
liver to an extent virtually identical with that noted for rat liver. 
For example, exposure of the human liver homogenate to 3 mM propionyl CoA 
reduced CPS I activity by 48%, an effect indistinguishable from the 52% 
inhibition observed under identical conditions with rat liver. 
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Discussion 
Hyperammonemia has been a common finding in infants with three 
disorders of organic acid metabolism, namely propionic, methylmalonic, 
and 0<-methylacetoacetic acidemias. The cause of this hyperammonemia is 
as yet unidentified, but it is likely that its occurrence contributes to 
the metabolic encephalopathy which is characteristic of children with 
these disorders. Previous work done in an attempt to link the primary 
defects in organic acid metabolism with this secondary biochemical 
abnormality indicates that ureagenesis is impaired either by decreasing the 
availability or impairing the action of one of the substrates, ATP, or 
the allosteric activator, NAG, of the CPS I reaction. 
The data presented in this paper demonstrate a different kind of 
inhibitory effect, namely a direct inhibition of CPS I activity by 
various acyl CoA's. While the organic acids tiglate, propionate, and 
methylmalonate had no effect on the three urea cycle enzymes measured, 
their CoA esters significnatly inhibited CPS I activity, but not that of 
OTC or arginase. In studies using the most potent of these CoA esters, 
propionyl CoA, inhibition in rat liver homogenates, disrupted mito¬ 
chondria, and purified enzyme was shown to be concentration-dependent. 
Inhibition in these preparations increased from about 35% at 1 mM propionyl 
CoA to 70% at 10 mM. 
These results differ from those rep rted in a previous study (92) 
in which 10 mM propionyl CoA inhibited CPS I activity in disrupted 
mitochondria by only 15% at 30 C. This difference was shown not to be 
temperature dependent since in the present experiments significant and 
equivalent inhibition of CPS I was demonstrated at both 30° C and 3/ C. 
I 
. 
(; 
The difference may be explained if the assays in the previous work 
were run in the presence of mercaptoethanol or another sulfhydryl reagent 
since I have shown that these agents protect CPS I from inhibition by 
propionyl CoA. Furthermore, the control activity measured by these 
o 
authors was only 50% of that seen at 30 C in the present experiments. 
This may reflect the presence of another inhibitor in the assays which 
complicated evaluation of CoA ester inhibition. 
The degree of inhibition that was demonstrated with 10 mM propionyl 
CoA is large enough to account for the hyperammonemia observed in_ vivo 
since patients with ammonia intoxication due to primary CPS I deficien¬ 
cies have been reported with as much as 40% residual CPS I activity (104). 
In addition, the preliminary studies presented here, in which propionyl CoA 
was incubated with homogenates prior to assaying CPS I activity, indicate 
that the inhibition of CPS I by propionyl CoA may also be time-dependent. 
Thus, the concentration of propionyl CoA needed to achieve marked 
inhibition of CPS I activity might be less than the 10 mM concentrations 
regularly employed to achieve 60% inhibition. In fact, incubation of 
homogenates with 2.5 mM propionyl CoA for 30 minutes followed by assay 
in the presence of 1 mM prcpionyl CoA resulted in 66% inhibition of 
CPS I activity. If the time that propionyl CoA builds up in these 
disorders, and hence the time of exposure to CPS I, is taken into account, 
propionyl CoA concentrations closer to the serum concentrations of 
propionate observed in patients with propionic acidemia will result in 
60% inhibition or more. 
It should be stressed that my results cannot be explained by the 
previous data which attributed the hyperammonemia to decreased availa¬ 
bility or action of NAG, since the present assays were run in the presence 
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of 10 mM NAG, 100 times the reported K (97). In addition, increasing 
cl 
the concentration of NAG to 100 mM had no effect on the degree of inhibition. 
The data obtained in these in_ vitro studies is consistent with 
what little in vivo information does exist. First, despite the lack 
of any measurements of intramitochondrial CoA concentrations in the 
tissues of patients with these inherited organic acidemias, Stewart and 
Walser (92) have shown that acyl CoA's (presumably propionyl and methyl- 
malonyl CoA's) increase in mitochondria isolated from rats injected with 
20 mmoles/kg propionate or methylmalonate. Since millimolar concentra¬ 
tions of the free acids have been reported in the blood (34) , it is 
plausible that the concentration of the CoA esters employed in our experi¬ 
ments may accumulate intramitochondrially iri vivo. Second, and of 
particular relevance, significantly reduced CPS I activities have been 
reported in children with these organic acidemias. In 1969, Kirkmann and 
Keisel (105) described a child with hyperammonemia and a selective 
deficiency of CPS I activity to 50% of control values who was subse¬ 
quently shown to have methylmalonic acidemia. More recently, Harris and 
colleagues reported selective CPS I deficiency to 20% of control values 
in a child with propionic acidemia (106). It is unlikely that these low 
CPS I values represent coexisting primary metabolic defects; rather it is 
likely that they are secondary to the defect in organic acid metabolism. 
Thirdly, other workers (107,108) have proposed that the hypoglycemia 
and hyperglycinemia often observed in patients with these organic 
acidemias may result from the intramitochondrial effects of CoA esters 
on gluconeogenesis and glycine cleavage, respectively. It is, therefore, 
attractive to propose that all of the major secondary biochemical ab¬ 
normalities observed in the organic acidemias may reflect CoA ester- 
V 
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mediated disturbances of selected mitochondrial functions. Finally, 
the present data, unlike those of other groups, can explain the hyper¬ 
ammonemia observed in all three disorders since tiglyl, methylmalonyl, 
and propionyl CoA's all exhibited significant inhibition of CPS I. 
Inhibition of NAG synthetase, on the other hand, cannot explain the 
hyperammonemia seen in patients with methylmalonic acidemia since 
methylmalonyl CoA inhibits this enzyme only to a small degree. 
These results provide little information as to the precise bio¬ 
chemical mechanism by which CoA and its derivatives impair hepatic CPS I 
activity. Results of the Michaelis-Menten analyses indicate that these 
CoA's do not compete with any of this complex enzyme's substrates for 
their binding sites since only the V 's and not the K 's were affected 
mcix m 
by propionyl CoA. The ability of dithiothreitol to decrease the degree 
of inhibition by propionyl CoA suggests that the CoA's act by interacting 
with sulfhydryl groups on the enzyme, either to alter the active site 
or change the conformation of the enzyme. The importance of sulfhydryl 
groups in CPS I has been studied and seems to be related to the stabiliza¬ 
tion of various conformations. Some sulfhydryl reagents like cysteine 
result in quick inactivation of the enzyme, which some authors (109) 
suggest may occur by the breaking of disulfide bonds leading to the 
dissociation of the dimer. This inactivation requires the presence of 
NAG (110). Since NAG effects a conformational change on CPS I, this 
change in tertiary structure may unmask a key sulfhydryl group with 
which cysteine can react. Other sulfhydryl reagents, such as mercapto- 
ethanol, dithiothreitol, and dithioerythritol, have been shown to stabilize 
the enzyme (97,111). The difference between these two groups of sulf- 
' 
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hydryl agents may be due to steric factors or the strength of the -SH 
groups themselves. In these experiments, dithiothreitol partially 
protected CPS I from inhibition by propionyl CoA. Propionyl CoA, then, 
may be acting to inhibit CPS I by forming a propionyl CoA-enzvme complex 
involving sulfhydryl groups or by accelerating the conformational change 
to its inactive form. If the latter mechanism is correct, one would 
predict that preincubation of CPS I with propionyl CoA would lead to 
inhibition even if the propionyl CoA were to be removed prior to 
assaying. The inability to demonstrate such an effect in these experiments 
(Table 5) may be secondary to the absence of NAG in the preincubation 
mixture, but it may argue against the formation of stable enzyme- 
inhibitor complexes. 
The hyperammonemia seen in patients with inherited organic acidemias 
appears to occur as the result of the buildup of acyl CoA intermediates 
in response to an amino acid load. The present data taken together 
with previous work suggests that the acyl CoA's may work at two sites: 
namely 1) to inhibit directly CPS I and 2) to decrease NAG availability 
and secondarily decrease CPS I activity. In addition, factors such as 
the availability of ATP, increased nitrogen turnover, and the rate of 
removal of these acyl CoA's may be important in the pathogenesis of the 
hyperammonemia. 
The relationship between the pathogenesis of the hyperammonemia seen 
in inherietd disorders of organic acid metabolism and that seen in other 
disorders such as Reye's Syndrome and hypoglycin toxicity (Jamaican 
vomiting sickness) remains to be demonstrated. Certainly many clinical 
and biochemical similarities exist including vomiting, lethargy, and 
coma as well as hypoglycemia and hyperammonemia. If the toxic agent 
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in each of these disorders inhibits one of the enzymes important for 
branched-chain amino acid metabolism, significant concentrations of acyl 
CoA's may accumulate. Alternatively, the toxic agents themselves may be 
metabolized to short chain fatty acids which could be converted to CoA 
esters. In either case, this buildup of acyl CoA's may inhibit CPS I and 
lead to hyperammonemia. 
Treatment of children with propionic, methylmalonic, and o(-methyl- 
acetoacetic acidemias consists of a diet low in the amino acids that enter 
the Krebs Cycle through methylmalonate: valine, isoleucine, methionine, 
and threonine. In patients who are recognized early, institution of such a 
diet has achieved excellent results (35) . In patients where these 
disorders are unexpected and in whom hyperammonemia occurs, early institu¬ 
tion of peritoneal dialysis is essential. If a decrease in INAGavaila- 
bility is important in the pathogenesis of the hyperammonemia, infusion 
of L-arginine and carbamylglutamate (since NAG has been shown to break 
down when administered intraperitoneally in rats) may ameliorate the 
hyperammonemia. To the extent that a direct effect on CPS I by increased 
levels of acyl CoA's is important iri vivo, administration of carbamyl¬ 
glutamate is unlikely to decrease ammonia levels, in light of the present 
work which fails to demonstrate a decrease in inhibition with increased 
concentrations of NAG in_ vitro. General support in the form of dialysis 
and removal of the offending amino acids may give some benefit. 
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